Terms ending in 2029
Every in-force patent on Ablynx N.V.'s record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,834,595 | Amino Acid Sequences Directed Against Envelope Proteins of a Virus and Polypeptides Comprising the Same for the Treatment of Viral Diseases In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 10,550,174 | Amino Acid Sequences Directed Against Envelope Proteins of a Virus and Polypeptides Comprising the Same for the Treatment of Viral Diseases In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 11,858,997 | Amino Acid Sequences That Modulate the Interaction Between Cells of the Immune System In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 9,156,914 | Amino Acid Sequences Directed Against a Metalloproteinase from the Adam Family and Polypeptides Comprising the Same for the Treatment of Adam-Related Diseases and Disorders In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 11,518,799 | Amino Acid Sequences Directed Against Envelope Proteins of a Virus and Polypeptides Comprising the Same for the Treatment of Viral Diseases In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 8,906,680 | Amino Acid Sequences Directed Against Chemokines and Polypeptides Comprising the Same for the Treatment of Chemokine-Related Diseases and Disorders In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 9,803,018 | Amino Acid Sequences Directed Against Cellular Receptors for Viruses and Bacteria In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 9,993,552 | Formulations of Single Domain Antigen Binding Molecules In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 8,188,223 | Serum Albumin Binding Proteins In force · Medium confidence | Ablynx N.V. | In force | Medium confidence | |
| US 8,557,965 | Single Variable Domains Against Notch Pathway Members In force · High confidence | Ablynx N.V. | In force | High confidence | |
| 4 more term ends in 2029 · Pro | |||||
10 of 14 patents shown. Soonest term end first, then patent number.
Pro members see all 14.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.